Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis

Enrico Tombetti, Chiara C. Di Chio, Silvia Sartorelli, Maurizio Papa, Annalaura Salerno, Barbara Bottazzi, Paola P. Bozzolo, Marta Greco, Patrizia Rovere-Querini, Elena Baldissera, Alessandro Del Maschio, Alberto Mantovani, Francesco De Cobelli, Grazia G. Sabbadini, Angelo A. Manfredi

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Introduction: Progression of arterial involvement is often observed in patients with Takayasu arteritis (TA) thought to be in remission. This reflects the failure of currently used biomarkers and activity criteria to detect smouldering inflammation occurring within arterial wall. Pentraxin-3 (PTX3) is a soluble pattern recognition receptor produced at sites of inflammation and could reveal systemic as well as localized inflammatory processes. We verified whether the blood concentrations of PTX3 and of C-reactive protein (CRP) in patients with Takayasu arteritis (TA) might reflect vascular wall involvement, as assessed by signal enhancement after contrast media administration, and the progression of arterial involvement. Methods: A cross-sectional single-centre study was carried out on 42 patients with TA that comprised assessment of PTX3, of CRP and erythrocyte sedimentation velocity (ESR). In total, 20 healthy controls and 20 patients with Systemic Lupus Erythematous (SLE) served as controls. Vascular imaging was carried out by magnetic resonance angiography, doppler ultrasonography and computed tomography angiography. Results: Patients with TA and SLE had higher plasmatic PTX3 and CRP concentrations than healthy controls (P = 0.009 and 0.017, respectively). PTX3 levels did not correlate with those of CRP. Patients with active systemic TA had significantly higher concentrations of CRP but similar levels of PTX3 than patients with quiescent disease. In contrast, patients with vascular inflammation detectable at imaging had higher PTX3 concentrations (P = 0.016) than those in which vessel inflammation was not evident, while CRP levels were similar. The concentration of PTX3 but not that of CRP was significantly higher in TA patients with worsening arterial lesions that were not receiving antagonists of tumor necrosis factor-α or interleukin-6. Conclusions: Arterial inflammation and progression of vascular involvement influence plasma PTX3 levels in TA, while levels of CRP accurately reflect the burden of systemic inflammation. These results support the contention that PTX3 reflects different aspects of inflammation than CRP and might represent a biomarker of actual arteritis in TA.

Original languageEnglish
Article number479
JournalArthritis Research and Therapy
Volume16
Issue number1
DOIs
Publication statusPublished - Nov 14 2014

Fingerprint

Takayasu Arteritis
Blood Vessels
C-Reactive Protein
Inflammation
Arteritis
Biomarkers
PTX3 protein
Pattern Recognition Receptors
Doppler Ultrasonography
Magnetic Resonance Angiography
Blood Sedimentation
Contrast Media
Interleukin-6
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. / Tombetti, Enrico; Di Chio, Chiara C.; Sartorelli, Silvia; Papa, Maurizio; Salerno, Annalaura; Bottazzi, Barbara; Bozzolo, Paola P.; Greco, Marta; Rovere-Querini, Patrizia; Baldissera, Elena; Del Maschio, Alessandro; Mantovani, Alberto; De Cobelli, Francesco; Sabbadini, Grazia G.; Manfredi, Angelo A.

In: Arthritis Research and Therapy, Vol. 16, No. 1, 479, 14.11.2014.

Research output: Contribution to journalArticle

Tombetti, Enrico ; Di Chio, Chiara C. ; Sartorelli, Silvia ; Papa, Maurizio ; Salerno, Annalaura ; Bottazzi, Barbara ; Bozzolo, Paola P. ; Greco, Marta ; Rovere-Querini, Patrizia ; Baldissera, Elena ; Del Maschio, Alessandro ; Mantovani, Alberto ; De Cobelli, Francesco ; Sabbadini, Grazia G. ; Manfredi, Angelo A. / Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. In: Arthritis Research and Therapy. 2014 ; Vol. 16, No. 1.
@article{287fe02b2dec4bffa2ec23c70b47d3df,
title = "Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis",
abstract = "Introduction: Progression of arterial involvement is often observed in patients with Takayasu arteritis (TA) thought to be in remission. This reflects the failure of currently used biomarkers and activity criteria to detect smouldering inflammation occurring within arterial wall. Pentraxin-3 (PTX3) is a soluble pattern recognition receptor produced at sites of inflammation and could reveal systemic as well as localized inflammatory processes. We verified whether the blood concentrations of PTX3 and of C-reactive protein (CRP) in patients with Takayasu arteritis (TA) might reflect vascular wall involvement, as assessed by signal enhancement after contrast media administration, and the progression of arterial involvement. Methods: A cross-sectional single-centre study was carried out on 42 patients with TA that comprised assessment of PTX3, of CRP and erythrocyte sedimentation velocity (ESR). In total, 20 healthy controls and 20 patients with Systemic Lupus Erythematous (SLE) served as controls. Vascular imaging was carried out by magnetic resonance angiography, doppler ultrasonography and computed tomography angiography. Results: Patients with TA and SLE had higher plasmatic PTX3 and CRP concentrations than healthy controls (P = 0.009 and 0.017, respectively). PTX3 levels did not correlate with those of CRP. Patients with active systemic TA had significantly higher concentrations of CRP but similar levels of PTX3 than patients with quiescent disease. In contrast, patients with vascular inflammation detectable at imaging had higher PTX3 concentrations (P = 0.016) than those in which vessel inflammation was not evident, while CRP levels were similar. The concentration of PTX3 but not that of CRP was significantly higher in TA patients with worsening arterial lesions that were not receiving antagonists of tumor necrosis factor-α or interleukin-6. Conclusions: Arterial inflammation and progression of vascular involvement influence plasma PTX3 levels in TA, while levels of CRP accurately reflect the burden of systemic inflammation. These results support the contention that PTX3 reflects different aspects of inflammation than CRP and might represent a biomarker of actual arteritis in TA.",
author = "Enrico Tombetti and {Di Chio}, {Chiara C.} and Silvia Sartorelli and Maurizio Papa and Annalaura Salerno and Barbara Bottazzi and Bozzolo, {Paola P.} and Marta Greco and Patrizia Rovere-Querini and Elena Baldissera and {Del Maschio}, Alessandro and Alberto Mantovani and {De Cobelli}, Francesco and Sabbadini, {Grazia G.} and Manfredi, {Angelo A.}",
year = "2014",
month = "11",
day = "14",
doi = "10.1186/s13075-014-0479-z",
language = "English",
volume = "16",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis

AU - Tombetti, Enrico

AU - Di Chio, Chiara C.

AU - Sartorelli, Silvia

AU - Papa, Maurizio

AU - Salerno, Annalaura

AU - Bottazzi, Barbara

AU - Bozzolo, Paola P.

AU - Greco, Marta

AU - Rovere-Querini, Patrizia

AU - Baldissera, Elena

AU - Del Maschio, Alessandro

AU - Mantovani, Alberto

AU - De Cobelli, Francesco

AU - Sabbadini, Grazia G.

AU - Manfredi, Angelo A.

PY - 2014/11/14

Y1 - 2014/11/14

N2 - Introduction: Progression of arterial involvement is often observed in patients with Takayasu arteritis (TA) thought to be in remission. This reflects the failure of currently used biomarkers and activity criteria to detect smouldering inflammation occurring within arterial wall. Pentraxin-3 (PTX3) is a soluble pattern recognition receptor produced at sites of inflammation and could reveal systemic as well as localized inflammatory processes. We verified whether the blood concentrations of PTX3 and of C-reactive protein (CRP) in patients with Takayasu arteritis (TA) might reflect vascular wall involvement, as assessed by signal enhancement after contrast media administration, and the progression of arterial involvement. Methods: A cross-sectional single-centre study was carried out on 42 patients with TA that comprised assessment of PTX3, of CRP and erythrocyte sedimentation velocity (ESR). In total, 20 healthy controls and 20 patients with Systemic Lupus Erythematous (SLE) served as controls. Vascular imaging was carried out by magnetic resonance angiography, doppler ultrasonography and computed tomography angiography. Results: Patients with TA and SLE had higher plasmatic PTX3 and CRP concentrations than healthy controls (P = 0.009 and 0.017, respectively). PTX3 levels did not correlate with those of CRP. Patients with active systemic TA had significantly higher concentrations of CRP but similar levels of PTX3 than patients with quiescent disease. In contrast, patients with vascular inflammation detectable at imaging had higher PTX3 concentrations (P = 0.016) than those in which vessel inflammation was not evident, while CRP levels were similar. The concentration of PTX3 but not that of CRP was significantly higher in TA patients with worsening arterial lesions that were not receiving antagonists of tumor necrosis factor-α or interleukin-6. Conclusions: Arterial inflammation and progression of vascular involvement influence plasma PTX3 levels in TA, while levels of CRP accurately reflect the burden of systemic inflammation. These results support the contention that PTX3 reflects different aspects of inflammation than CRP and might represent a biomarker of actual arteritis in TA.

AB - Introduction: Progression of arterial involvement is often observed in patients with Takayasu arteritis (TA) thought to be in remission. This reflects the failure of currently used biomarkers and activity criteria to detect smouldering inflammation occurring within arterial wall. Pentraxin-3 (PTX3) is a soluble pattern recognition receptor produced at sites of inflammation and could reveal systemic as well as localized inflammatory processes. We verified whether the blood concentrations of PTX3 and of C-reactive protein (CRP) in patients with Takayasu arteritis (TA) might reflect vascular wall involvement, as assessed by signal enhancement after contrast media administration, and the progression of arterial involvement. Methods: A cross-sectional single-centre study was carried out on 42 patients with TA that comprised assessment of PTX3, of CRP and erythrocyte sedimentation velocity (ESR). In total, 20 healthy controls and 20 patients with Systemic Lupus Erythematous (SLE) served as controls. Vascular imaging was carried out by magnetic resonance angiography, doppler ultrasonography and computed tomography angiography. Results: Patients with TA and SLE had higher plasmatic PTX3 and CRP concentrations than healthy controls (P = 0.009 and 0.017, respectively). PTX3 levels did not correlate with those of CRP. Patients with active systemic TA had significantly higher concentrations of CRP but similar levels of PTX3 than patients with quiescent disease. In contrast, patients with vascular inflammation detectable at imaging had higher PTX3 concentrations (P = 0.016) than those in which vessel inflammation was not evident, while CRP levels were similar. The concentration of PTX3 but not that of CRP was significantly higher in TA patients with worsening arterial lesions that were not receiving antagonists of tumor necrosis factor-α or interleukin-6. Conclusions: Arterial inflammation and progression of vascular involvement influence plasma PTX3 levels in TA, while levels of CRP accurately reflect the burden of systemic inflammation. These results support the contention that PTX3 reflects different aspects of inflammation than CRP and might represent a biomarker of actual arteritis in TA.

UR - http://www.scopus.com/inward/record.url?scp=84924340870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924340870&partnerID=8YFLogxK

U2 - 10.1186/s13075-014-0479-z

DO - 10.1186/s13075-014-0479-z

M3 - Article

C2 - 25394473

AN - SCOPUS:84924340870

VL - 16

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

M1 - 479

ER -